secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-05-27T20:01:34+00:00
Accession:  0001140361-26-022979
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026
--------------------------------------------------------------------

- FDA accepted NDA with Priority Review for BBP-418 to treat LGMD2I/R9; PDUFA target action date November 27, 2026.
- No advisory committee meeting currently planned for the application.
- Phase 3 FORTIFY trial met all primary and secondary endpoints; treated patients improved while placebo declined.
- If approved, BBP-418 would be first and only therapy for LGMD2I/R9 and first approved treatment for any form of LGMD.
- BridgeBio plans to start studies in patients under 12 years and in LGMD2M/R13 and LGMD2U/R20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/0001140361-26-022979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-022979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer